Clinical Trial Update: A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates for APL-9 in adults with mild to moderate ARDS due to COVID-19 have completed Phase 1 and Phase 2; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• APL-9 (APL-9)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: COVID, Covid-19 | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-03-23